Also known as Dexilant
Dexlansoprazole (INN, trade names Kapidex, Dexilant) is a proton pump inhibitor that is marketed by Takeda Pharmaceuticals. Chemically, it is an enantiomer of lansoprazole. The compound was launched in the US for use in the treatment and maintenance of patients with erosive oesophagitis and non-erosive gastro-oesophageal reflux disease (GERD or GORD). Dexlansoprazole was approved by the U.S. Food and Drug Administration (FDA) on January 30, 2009. Of note, lansoprazole (originally sold under the brand name Prevacid) is available as a generic and generally sold at a far lower cost than dexlansoprazole. There is no evidence that dexlansoprazole provides any clinical benefits over lansoprazole, rendering the higher price of dexlansoprazole somewhat questionable.Source: Wikipedia
Estimated Total Cost: $111.78 for an average of 28 days supply
Patients are most commonly prescribed dexlansoprazole to treat gastroesophageal reflux disease (gerd), upper abdominal pain, heartburn, and gastritis.